Health Jul 12 Trump administration’s NIH funding cuts threaten research on sickle cell disease By Ali Rogin, Kaisha Young
Health Dec 09 Watch 5:08 Why the FDA’s approval of revolutionary sickle cell gene therapy is a ‘big deal’ Sickle cell disease is a chronic, debilitating condition that affects nearly 100,000 Americans, most of them with African ancestry. Now, the FDA has approved a groundbreaking treatment for it that uses the gene-editing tool CRISPR. John Yang speaks with Yale… By John Yang, Claire Mufson, Harry Zahn
Health Dec 08 Gene therapies for sickle cell disease approved in U.S. Regulators on Friday approved two new gene therapies for sickle cell disease that doctors hope can cure the painful, inherited blood disorder that afflicts mostly Black people in the United States. By Laura Ungar, Associated Press
Health Nov 16 The world’s first gene therapy for sickle cell disease has been approved in the UK In a statement on Thursday, the Medicines and Healthcare Regulatory Agency said it had approved Casgevy, the first medicine licensed using the gene editing tool CRISPR, which won its makers a Nobel prize in 2020. By Maria Cheng, Associated Press
Health Oct 31 WATCH: Sickle cell gene therapy gets review from FDA advisory committee If approved, it would be the first gene therapy on the U.S. market based on CRISPR, the gene editing tool that won its inventors the Nobel Prize in 2020. By Laura Ungar, Associated Press
Nov 20 First CRISPR treatment for sickle cell, other blood disease shows early benefits in two patients By Sharon Begley, Adam Feuerstein, STAT The first two patients to receive a CRISPR-based treatment for the inherited blood disorders sickle cell disease and beta thalassemia have benefited from the experimental therapy and experienced only temporary and treatable side effects. Continue reading
Nov 15 U.S. approves new drug to manage sickle cell disease, costs $85,000 to $113,000 By Linda A. Johnson, Associated PRess The monthly infusion, which halves occurrences of sickle cell pain episodes, will carry a list price of roughly $85,000 to $113,000 per year, depending on dosing. Insured patients generally will pay less. Continue reading
Dec 30 Sickle cell patients, families and doctors face a ‘fight for everything’ By Jenny Gold, Kaiser Health News Premature death, a dearth of treatments, mistreatment in emergency rooms and a woeful lack of funding are just a few of the problems. Continue reading
Jun 22 Prodigy’s death shines light on slow progress against sickle cell disease By Sharon Begley, STAT The death of the rap artist Prodigy (Albert Johnson) at only 42 this week, after a lifetime of suffering from sickle cell disease, was a reminder of the devastating cost of the sometimes fatal genetic disorder — and of the… Continue reading